دورية أكاديمية
White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer
| العنوان: | White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer |
|---|---|
| المؤلفون: | Leal, Alessandro, van Grieken, Nicole C. T., Palsgrove, Doreen N., Phallen, Jillian, Medina, Jamie E., Hruban, Carolyn, Broeckaert, Mark A. M., Anagnostou, Valsamo, Adleff, Vilmos, Bruhm, Daniel C., Canzoniero, Jenna V., Fiksel, Jacob, Nordsmark, Marianne, Warmerdam, Fabienne A. R. M., Verheul, Henk M. W., van Spronsen, Dick Johan, Beerepoot, Laurens V., Geenen, Maud M., Portielje, Johanneke E. A., Jansen, Edwin P. M., van Sandick, Johanna, Meershoek-Klein Kranenbarg, Elma, van Laarhoven, Hanneke W. M., van der Peet, Donald L., van de Velde, Cornelis J. H., Verheij, Marcel, Fijneman, Remond, Scharpf, Robert B., Meijer, Gerrit A., Cats, Annemieke, Velculescu, Victor E. |
| المساهمون: | U.S. Department of Health & Human Services | NIH | National Cancer Institute, EIF | Stand Up To Cancer, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Mark Foundation for Cancer Research |
| المصدر: | Nature Communications ; volume 11, issue 1 ; ISSN 2041-1723 |
| بيانات النشر: | Springer Science and Business Media LLC |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | General Physics and Astronomy, General Biochemistry, Genetics and Molecular Biology, General Chemistry, Multidisciplinary |
| الوصف: | Liquid biopsies are providing new opportunities for detection of residual disease in cell-free DNA (cfDNA) after surgery but may be confounded through identification of alterations arising from clonal hematopoiesis. Here, we identify circulating tumor-derived DNA (ctDNA) alterations through ultrasensitive targeted sequencing analyses of matched cfDNA and white blood cells from the same patient. We apply this approach to analyze samples from patients in the CRITICS trial, a phase III randomized controlled study of perioperative treatment in patients with operable gastric cancer. After filtering alterations from matched white blood cells, the presence of ctDNA predicts recurrence when analyzed within nine weeks after preoperative treatment and after surgery in patients eligible for multimodal treatment. These analyses provide a facile method for distinguishing ctDNA from other cfDNA alterations and highlight the utility of ctDNA as a predictive biomarker of patient outcome to perioperative cancer therapy and surgical resection in patients with gastric cancer. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1038/s41467-020-14310-3 |
| الإتاحة: | https://doi.org/10.1038/s41467-020-14310-3Test https://www.nature.com/articles/s41467-020-14310-3.pdfTest https://www.nature.com/articles/s41467-020-14310-3Test |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test ; https://creativecommons.org/licenses/by/4.0Test |
| رقم الانضمام: | edsbas.ECF25BB9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1038/s41467-020-14310-3 |
|---|